The relationship between oxidative stress marker and atherosclerosis in diabetes hyperlipidemic patient
DOI:
https://doi.org/10.61841/3wtze470Keywords:
Hyperglycemia, Dyslipidemia, Glutathione peroxidase, HbA1c, CRPAbstract
Diabetes mellitus can defined as disease characterized by many metabolic abnormalities like increased in blood glucose level (hyperglycemia) and failure in either synthesis or action of insulin that synthesized in the body by β-cell of pancreas, this disease accompanied by high mortality and morbidity due to the high percentage of exposure to cardiovascular complications (CVD). Seventy five people included in this study, all from Al-Kadhmiya Teaching Hospital during period from December 2019 to February 2020, study design (case –control study). Subjects were divided into two groups: 1- Control group (non- patient group): involve 50 healthy subjects 2-Patient study group: involve 25 diabetic hyperlipidemic subjects. All patients were diagnosed with hyperglycemia have Fasting blood sugar (FBS 125 – 300 mg/dl) with age between ( 40 – 65 years) and BMI (29.8% – 33%) and suffering of dyslipidemia; while control group have (FBS 74 – 120 mg/dl) and with age between ( 40 – 65 years) and BMI ( 28% - 31%)with normal lipid profile. There was significantly increasing in mean value of HbA1c, lipid profile, CRP and glutathione peroxidase in diabetic patient group than healthy control people (p<0.001) We can conclude that accelerated factors of atherosclerosis in diabetic patients is hyperglycemia in addition to dyslipidemia and increasing oxidative stress that lead to production of inflammatory factors and promote inflammatory reaction with blood vessels wall.
Diabetic hyperlipidemic vasculature is a key mediator for atherosclerosis
Downloads
References
1) Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions,1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224–2260.
2) Kangralkar, V.A., Patil, S.D., Bandivadekar, R.M., 2010. Oxidativestress and diabetes: a review. Int. J. Pharm. Appl. 1 (1), 38–45.
3) The Emerging Risk Factors Collaboration Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
4) Bornfeldt KE, Tabas I. Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metab 2011; 14: 575.
5) Liang CP, Han S, Senokuchi T, Tall AR. The Macrophage at the Crossroads of Insulin Resistance and Atherosclerosis. Circ Res 2007; 100: 1546-1555.
6) Vasquez-Trincado C, Garcia-Carvajal I, Pennanen C, Parra V, Hill JA, Rothermel BA, Lavandero S. Mitochondrial dynamics, mitophagy and cardiovascular disease. J Physiol. 2016; 594: 509-5257). 7)Makino A, Scott BT, Dillmann WH. Mitochondrial fragmentation and superoxide anion production in coronary endothelial cells from a mouse model of type 1 diabetes. Diabetologia. 2010; 53: 1783-1794.
8) Matough, F.A., Budin, S.B., Hamid, Z.A., Alwahaibi, N., Mohamed,J., 2012. The role of oxidative stress and antioxidants in diabeticcomplications. Sultan Qaboos Univ. Med. J. 12 (1), 5–18.
9) Tiwari, B.K. et al, 2013. Markers of oxidative stress during diabetes mellitus. J. Biomarkers (Article ID 378790).
10) Shrikhande GV, Scali ST, da Silva CG, Damrauer SM, Csizmadia E, Putheti P, Matthey M, Arjoon R, Patel R, Siracuse JJ, Maccariello ER, Andersen ND, Monahan T, Peterson C, Essayagh S, Studer P, Guedes RP, Kocher O, Usheva A, Veves A, Kaczmarek E, Ferran C. O-glycosylation regulates ubiquitination and degradation of the antiinflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice. PLoS One. 2010; 5: e14240. 10.1371/journal.pone.0014240
11) Makino A, Dai A, Han Y, Youssef KD, Wang W, Donthamsetty R, Scott BT, Wang H, Dillmann WH. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice. Am J Physiol Cell Physiol. 2015; 309: C593-C599.
12) Joshi MB, Lad A, Bharath Prasad AS, Balakrishnan A, Ramachandra L, Satyamoorthy K. High glucose modulates IL-6 mediated immune homeostasis through impeding neutrophil extracellular trap formation. FEBS letters 2013; 587: 2241-2246.
13) Zimmer S, Grebe A, Latz E. Danger signaling in atherosclerosis. Circ Res 2015; 116: 323-340.
14) Demer LL and Tintut Y. Interactive and multifactorial mechanisms of calcific vascular and valvular disease.
15) Nahrendorf M, Swirski FK. Immunology. Neutrophil-macrophage communication in inflammation and atherosclerosis. Science. 2015; 349: 237-238.
16) Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: The ARIC (Atherosclerosis Risk In Communities)study. J Am Coll Cardiol 2010; 55: 1600–1607.
17) Yla¨ -Herttuala, S., 1999. Oxidized LDL and atherogenesis. Ann. N.Y.Acad. Sci. 874, 134–137.
18) King G.L. Shiba T. Oliver J. Inoguchi T. Bursell S.E. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus Annu. Rev. Med. 1994 45 179 188.
19) Koya D. King G.L. Protein kinase C activation and the development of diabetic complications Diabetes 1998 47 859 866.
20) Patricia P.M. Reactive species and diabetes: counteracting oxidative stress to improve health.
Curr. Opin. Pharmacol. 2009;9:771–779.
21) Bornfeldt KE, Tabas I. Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metab 2011; 14: 575-585.
22) Guiotto, Andrea; Calderan, Andrea; Ruzza, Paolo; Borin, Gianfranco (1 September 2005). "Carnosine and Carnosine-Related Antioxidants: A Review". Current Medicinal Chemistry. 12 (20): 2293–2315.
23) Rahbar, S; Figarola, JL (2013-03-25). "Novel inhibitors of advanced glycation endproducts".
Arch. Biochem. Biophys. 419 (1): 63–79.
24) M.E. Rać, K. Safranow, M. Rać, G. Kurzawski, A. Krzystolik, D. Sagasz-Tysiewicz, K. Jakubowska, W. Poncyljusz, D. ChlubekCD36 gene is associated with thickness of atheromatous plaque and ankle-brachial index in patients with early coronary artery disease Kardiol. Pol., 70 (2012), pp. 918-923.
25) H. Sawada, Y. Saito, N. NoguchiEnhanced CD36 expression changes the role of Nrf2 activation from anti-atherogenic to pro-atherogenic in apoE-deficient mice Atherosclerosis, 225 (2012), pp. 83-90, 10.1016/j.atherosclerosis.2012.08.023.
26) Klein R.L. Laimins M. Lopes-Virella M.F. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects Diabetes 1995 44 1093 1098.
27) Prasad, Anand; Bekker, Peter; Tsimikas, Sotirios (2012). "Advanced Glycation End Products and Diabetic Cardiovascular Disease". Cardiology in Review. 20 (4): 177–183.
28) Di Marco, Elyse; Gray, Stephen P.; Jandeleit-Dahm, Karin (2013). "Diabetes Alters Activation and Repression of Pro- and Anti-Inflammatory Signaling Pathways in the Vasculature". Frontiers in Endocrinology. 4: 68.
29) Jinnouchi Y, Sano H, Nagai R, Hakamata H, Kodama T, Suzuki H, Yoshida M, Ueda S, Horiuchi S. Glycoaldehide-modified low density lipoprotein leads macrophages to foam cells via the macrophage scavenger receptor. J Biochem 1998; 123: 1208-1217.
30) Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990; 173: 932-939.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
